Centene Takes a Dose of Deal-Making
299575
The mergers and acquisitions continue apace in the managed care industry.
727972
When Inhibitex Inc. set the terms of its initial public offering in March, it thought it was being conservative, expecting shares to sell for $10 to $12 apiece.
435276
The troubled pharmaceutical company begins to show signs of life.
561268
Wine company Chalone thought it had a deal. Now it has better one.
280221
The pipeline drugs hold promise, but it will be a while before the company shows a profit.
464427
The company's distribution deal will have a big impact on its competitive strength.
714241
Synta Pharmaceuticals Corp. knows a thing or two about developing drugs. It has pretty impressive skills when it comes to money, too.
254105
The chip company makes a major deal to reach a new market.
110366
Deals are sprouting everywhere. One for the electronic trader might be on tap.
75207
We tend to concentrate on deals that have been cleverly played or defended, but in the real world everyone makes mistakes. When an opponent does something wrong, you must be ready to benefit.
504273
Cephalon's promotion of its pain drug Actiq might have crossed the line.
607266
The transaction, between the company and a group of private investors, would be one of the biggest deals to take a company private
110046
Some business software vendors are determined to steer their own ships in a sea of acquisitions.
350122
A closer look at the cash flow-generating capabilities of this smaller brand licensor.
227772
The pharmaceutical sells European rights to a promising asthma drug.
179498
PeopleSoft's board is willing to talk about a deal if the price is right.
664968
Promising drug test results make this a company to watch.